ONCO — Oncopeptides AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK1.33bn
- SEK1.39bn
- SEK31.65m
Annual cashflow statement for Oncopeptides AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1,591 | -1,421 | -349 | -253 | -283 |
| Depreciation | |||||
| Non-Cash Items | 161 | -44.3 | 19.2 | 9.22 | 8.87 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 134 | -51.1 | -108 | -46.3 | 4.31 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1,297 | -1,516 | -421 | -279 | -261 |
| Capital Expenditures | -17.2 | -0.339 | -2.51 | -0.116 | -0.357 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -2.95 | 0 | 0 | 0 | 0.853 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -20.1 | -0.339 | -2.51 | -0.116 | 0.496 |
| Financing Cash Flow Items | -76.2 | -56.6 | -28.1 | 0 | -41.6 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1,323 | 1,034 | 392 | 107 | 264 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -85.9 | -478 | -17.7 | -171 | 5.13 |